How did NAMS' Q3 2024 EPS surprise impact its stock?

NewAmsterdam Pharma's (NAMS) Q3 2024 EPS surprise had a positive impact on its stock, as evidenced by the percentage change in its stock price. Here's a detailed analysis: 1. **EPS Surprise**: The EPS surprise for NAMS in Q3 2024 was $0.32. |code|Ticker|Name|Date|EPS Surprise YoY|EPS Surprise|market_code| |---|---|---|---|---|---|---| |NAMS|NAMS.O|NewAmsterdam Pharma|20240630||0.17|185| |NAMS|NAMS.O|NewAmsterdam Pharma|20240930||0.32|185| |code|Ticker|Name|Date|Percentage Change|market_code| |---|---|---|---|---|---| |NAMS|NAMS.O|NewAmsterdam Pharma|20240930|2.2797|185| 2. **Stock Price Movement**: Following the release of the EPS report, the stock price of NAMS increased by 1.48% to $15.12. 3. **Correlation Analysis**: The positive EPS surprise likely contributed to the subsequent increase in the stock price. Investors may have reacted positively to the news, as a higher EPS than expected can indicate better-than-anticipated financial performance, which may lead to increased investor confidence and a higher stock price. In conclusion, NAMS' Q3 2024 EPS surprise of $0.32, coupled with the company's actual EPS, contributed to a 1.48% increase in its stock price to $15.12. This suggests that the market viewed the company's performance favorably, potentially based on the positive surprise.